Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Satoshi Soen"'
Autor:
Shiro Tanaka, Mitsuru Saito, Hiroshi Hagino, Satoshi Mori, Toshitaka Nakamura, Hiroaki Ohta, Teruki Sone, Kaito Takahashi, Yuji Mitomo, Toshitsugu Sugimoto, Satoshi Soen, Adequate Treatment of Osteoporosis (A‐TOP) Research Group
Publikováno v:
JBMR Plus, Vol 6, Iss 10, Pp n/a-n/a (2022)
ABSTRACT Associations between urinary pentosidine, one of the advanced glycation end products in collagen, and the risk of fracture in patients with severe osteoporosis are unknown. In this study, we investigated whether the urinary pentosidine level
Externí odkaz:
https://doaj.org/article/71fe7b52e9f94b0aa46eb544cbcbed22
Publikováno v:
Osteoporosis and Sarcopenia, Vol 6, Iss 4, Pp 191-198 (2020)
Objectives: This postmarketing study aims to evaluate the safety and effectiveness of oral administration of risedronate at 75 mg once monthly for 36 months in patients with osteoporosis in Japan. Methods: Participants were ambulatory outpatients wit
Externí odkaz:
https://doaj.org/article/68a22362006243ba9c2a7870b6ff5a12
Autor:
Yusuke Karasawa, Isao Kamae, Kazutaka Nozawa, Shigeki Zeniya, Tatsunori Murata, Satoshi Soen, Choitsu Sakamoto
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0253547 (2021)
ObjectivesThe aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost infor
Externí odkaz:
https://doaj.org/article/a82f2f647e3a4de9bc76e1b060bb65d1
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 107:e4222-e4231
ContextAbaloparatide reduced fracture risk in postmenopausal women with osteoporosis in the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE). Its effect in Japanese patients remains unexamined.ObjectiveThis work aimed to determine the e
Publikováno v:
Journal of Bone and Mineral Metabolism. 40:636-647
Glucocorticoid-induced osteoporosis (GIOP) is associated with elevated fracture risk. Practice guidelines have been published to reduce this risk but are insufficiently followed in everyday practice. The objectives of this study were to estimate frac
Publikováno v:
Modern Rheumatology. 32:634-640
Objectives A post hoc analysis of the Teriparatide Once-Weekly Efficacy Research for Glucocorticoid-induced Osteoporosis (TOWER-GO) study was performed to examine the effect of once-weekly administration of 56.5 μg teriparatide on primary prevention
Publikováno v:
Journal of Bone and Mineral Metabolism. 39:612-622
Osteoporotic fractures are the most common serious consequence of osteoporosis. Patients who suffer such fractures often require caregiver assistance afterwards. This study characterized the humanistic burden experienced by family caregivers of patie
Publikováno v:
Modern Rheumatology; May2022, Vol. 32 Issue 3, p634-640, 7p
Publikováno v:
Osteoporosis and Sarcopenia, Vol 6, Iss 4, Pp 191-198 (2020)
Osteoporosis and Sarcopenia
Osteoporosis and Sarcopenia
Objectives: This postmarketing study aims to evaluate the safety and effectiveness of oral administration of risedronate at 75 mg once monthly for 36 months in patients with osteoporosis in Japan. Methods: Participants were ambulatory outpatients wit
Publikováno v:
Journal of Bone and Mineral Metabolism. 39:446-455
Bisphosphonates are the standard treatment for glucocorticoid-induced osteoporosis (GIOP) with teriparatide being another option. While daily teriparatide has been shown to be effective in increasing bone mineral density (BMD), the efficacy of once-w